Skip to main content

Table 1 Studies with evidences for indirect fetotoxicity pathways without placental transfer of NMs

From: Recent insights on indirect mechanisms in developmental toxicity of nanomaterials

NP type/coating

NP size

exposure/model

application route/dose/exposure period

placental transfer

developmental toxicity (gestational and litter parameters)

developmental toxicity (other parameters)

hypothesis by authors on indirect toxicity pathways

publication

TiO2

5–6 nm

mouse

i.v./ 100 or 1000 μg/mouse/ GD9

not detected in fetus or placenta by ICP-MS

no overt fetal malformations or changes in pregnancy outcomes/ no impact on postnatal growth

behavioral deficits relevant to ASD and related neurodevelopmental disorders in neonates

maternal mediated unknown pathways due to absence of particles in placenta and fetal tissues

[75]

TiO2/CeO2

12.3 ± 0.1/ 22.4 ± 0.2 nm

mouse

instillation/ total 300 μg/mouse/ 100 μg at GD 2.5, GD 9.5 and GD 16.5)

Ti and Ce detected in the placenta but not in fetal tissues by ICP-MS

not evaluated

long-lasting impairment of lung development in offspring/ decreased placental efficiency together with the presence of NPs in the placenta/ no increase of inflammatory mediators in amniotic fluid, placenta or offspring lungs/ decreased pulmonary expression of VEGF-α and MMP-9 at the fetal stage (GD 17.5) and FGF-18 at the alveolarization stage (postnatal day 14.5)

probably involves placental insufficiency secondary to the presence of NPs in this organ with ensuing down regulation of critical mediators of lung development without any amniotic fluid or fetal lung inflammation/ not mediated via fetal or maternal lung inflammation

[76]

UV-Titan L181/polyalcohols

20.6 ± 0.3 nm

mouse

inhalation/ 1 h/day to 42 mg/m3/ GD 8–18

not detected in fetal liver by ICP-MS

no impact on gestational and litter parameters

moderate neurobehavioural deficits/ persistent lung inflammation in pregnant dams

dissolution and translocation of contaminating metal ions/ placental transfer of inflammatory cytokines released from NP-exposed maternal lung tissue

[77]

CuO

16 nm

mouse

inhalation/ 3.5 mg/m3 for 4 h/day/ GD 3–19

not detected by ICP-MS (similar Cu levels in placenta and fetus as controls)

survival rate of 7 week old pups reduced/ no impact on litter size, male/female ratio, body weight and lenght at birth

maternal pulmonary inflammation/ no histopathological changes of placenta tissue/ immunomodulatory effects in offspring (differential expression of several Th1/Th2 or other immune response genes in spleen)

changes in maternal inflammatory and immune responses

[78]

CdO

11–15 nm

mouse

inhalation/ 100 μg/m3 every other day or 230 μg/m3 daily for 2.5 h/ GD 4.5–16.5

Cd detected in placenta but not in fetus by gAAS and ICP-MS (Cd in placenta)

decreased incidence of pregnancy/ decreased fetal length/ delayed neonatal growth/ delayed maternal weight gain

altered placental weight

disruption in placental oxygen transfer by Cd [79]/ decrease in fetal length could be due to alterations in the fetal and/or maternal IGF system [80, 81]/ changes in the placental transport of zinc, vitamin B12, and other micronutrients due to placental Cd [82]

[83]

SWCNT /OH-functionalized

1–2 nm diameter and 5–30 μm length

mouse

oral/ 10 mg/kg or 100 mg/kg/ GD 9

not detected in placenta, fetal liver and fetal kidney by TEM

increased fetal resorption and fetal morphological and skeletal abnormalities at 10 mg/kg but not at higher dose

none

oxidative stress and inflammatory response in placenta/maternal tissue

[84]

SWCNT/non-oxidized, oxidized and ultra-oxidized

2.37 nm diameter, 0.85 μm length/ 1.58 nm diameter, 0.76 μm length/1.8 nm diameter, 0.37 μm length

mouse

i.v./ 10 ng to 30 μg/mouse/ GD 5.5

not detected by histological and micro-Raman analyses

high percentage of early miscarriages and fetal malformations; lowest effective dose 100 ng/mouse

vascular lesions and increased ROS in placenta/ increased ROS in malformed fetuses/ no increased ROS or evident morphological alterations in maternal tissues

oxidative stress in placental tissue

[85]

CoCr

29 nm

BeWo Transwell bilayer with underlying BJ fibroblasts

40 μg/ml/ 24 h

not detected by ICP-MS (similar Co and Cr levels in whole fetus as controls)

not applicable

DNA damage to the fibroblasts without significant cell death/ mechanism involving transmission of purine nucleotides (e.g. ATP) and intercellular signalling within the placental barrier through connexin gap junctions or hemichannels and pannexin channels

fetal damage mediated by placental tissue via release of mediators (e.g. ATP)

[86]

CoCr

29 nm

Bewo Transwell mono- or bilayers with underlying BJ fibroblasts or Oct4-hES

40 μg/ml / 24 h

not detected [86]

not applicable

DNA damage to fibroblasts or Oct4- hES cells only with BeWo double layer

indirect toxicity only across bilayered (human)/multilayered (mice) placental barrier

[87]

mouse

i.v./ 0.12 mg or 0.012 mg/mouse/ GD 9.5 or 12.5

not detected by ICP-MS (similar Co and Cr levels in whole fetus as controls)

no pathological changes in neonatal visceral organ

DNA damage in neonatal blood and liver at GD 12.5 (placenta with three layers established) but not at GD 9.5 (nutrient exchange via uterus and yolk sac)/ no pathological changes in placenta

CoCr

29 nm

Bewo Transwell bilayers and conditioned media transfer to NPC or NPC-derived astrocytes and neurons

40 μg/ml / 24 h

not detected [86]

not applicable

altered differentiation of human NPC and DNA damage in the derived neurons and astrocytes/ importance of autophagy and IL-6 release from placental tissue in NP-induced DNA-damaging singalling/ NPs can cause developmental neurotoxicity across placental barriers/ astrocytes are key mediators of this neurotoxicity/ fetal hippocampus is particularly affected in mice

exposure of the human placenta to CoCr NPs could initiate a singalling cascade that perturbs the relationship between astrocytes and neurons during neurodevelopment

[88]

mouse

i.v./ 0.12 mg / dpc 9

not detected [87]

see [87]

  1. ASD autism spectrum disorders, gAAS graphite furnace atomic absorption spectroscopy, FGF-18 fibroblast growth factor 18, GD gestation day, ICP-OES inductively coupled plasma optical emission spectrometry, IGF insulin growth factor, i.v. intravenous, MMP-9 matrix metalloproteinase 9, NP nanoparticles, NPC neural progenitor cells, ROS reactive oxygen species, TEM transmission electron microscopy. VEGF-α vascular endothelial growth factor α